Skip to main content

Neurovascular Diseases

Stroke is a medical emergency and one of the leading causes of death and disability worldwide. In this context, the Neurovascular Diseases Group was established in 2001, focusing on biomedical research into both ischemic and hemorrhagic stroke from a basic and translational perspective. Our work in this research field has covered the entire disease spectrum, from prevention and treatment to recovery. In 2017, we expanded our research interests to include vascular dementia and Alzheimer’s disease, related to the β-amyloid protein. Our ultimate goal as a research team is to help answer critical questions that will improve the clinical management of stroke and dementia, conditions with significant health impacts due to their high prevalence and associated disability. We are also committed to promoting scientific education among researchers and the society, and to fostering public engagement in these areas.

Since 2001, dozens of researchers have carried out their work in this laboratory, and as a team we have leaded translational and clinical projects through both preclinical studies with experimental models, as well as cohort studies in patients. The laboratory stands out for its extensive national and international collaborations, working closely with other research groups and the biomedical industry.

Publications

Nighttime hypoxia affects global cognition, memory, and executive function in community-dwelling individuals with hypertension.

PMID: 31992414
Journal: Journal of Clinical Sleep Medicine
Year: 2020
Reference: J Clin Sleep Med. 2020 Feb 15;16(2):243-250. doi: 10.5664/jcsm.8174. Epub 2020 Jan 13.
Impact factor: 3.586
Publication type: Paper in international publication
Authors: Riba-Llena, Iolanda, Alvarez-Sabin, Jose, Romero, Odile, Santamarina, Estevo, Sampol, Gabriel, Maisterra, Olga, Ferre, Alex, Montaner, Joan, Quintana, Manuel, Delgado, Pilar et al.
DOI: 10.5664/jcsm.8174

Endovascular Stroke Treatment and Risk of Intracranial Hemorrhage in Anticoagulated Patients.

PMID: 31992179
Journal: STROKE
Year: 2020
Reference: Stroke. 2020 Mar;51(3):892-898. doi: 10.1161/STROKEAHA.119.026606. Epub 2020 Jan 29.
Impact factor: 7.19
Publication type: Paper in international publication
Authors: Seiffge, David J, Meinel, Thomas R, Kniepert, Joachim U, Fischer, Urs, Auer, Elias, Frey, Sebastien, Goeldlin, Martina, Mordasini, Pasquale, Mosimann, Pascal J, Nogueira, Raul G et al.
DOI: 10.1161/STROKEAHA.119.026606

Circulating Aquaporin-4 as a biomarker of early neurological improvement in stroke patients: a pilot study.

PMID: 31672489
Journal: NEUROSCIENCE LETTERS
Year: 2020
Reference: Neurosci Lett. 2020 Jan 1;714:134580. doi: 10.1016/j.neulet.2019.134580. Epub 2019 Oct 28.
Impact factor: 2.274
Publication type: Paper in international publication
Authors: Ramiro, Laura, Simats, Alba, Penalba, Anna, Garcia-Tornel, Alvaro, Rovira, Alex, Mancha, Fernando, Bustamante, Alejandro, Montaner, Joan et al.
DOI: 10.1016/j.neulet.2019.134580

Blog

News

For three days, the III Stroke Congress of the national RICORS-ICTUS network and a symposium focused on cerebral haemorrhage were held.

The TOUCH MSCA-COFUND doctoral training programme, led by UAB and focusing on the field of mental health, has opened its first call for applications, offering 13 doctoral positions.

The Cardiovascular Diseases and Neurovascular Diseases groups at VHIR will investigate new therapeutic strategies for heart failure, nanomedicine in stroke and the prevention of cardiovascular toxicity in the case of oncological treatments.